Avelox and Vigamox (moxifloxacin) are fluoroquinolones in two product families, 400 mg tablets and 400 mg/250 mL infusion for systemic use and 0.5% eye drops for bacterial conjunctivitis, and none of them needs refrigeration on the labels we read.

Moxifloxacin exporter and bulk supplier from India.

"We need a partner for moxifloxacin" can mean two different enquiries. A hospital pharmacy asking for Avelox wants a systemic antibacterial: 400 mg film-coated tablets and, on the US label, a 400 mg premix bag in 250 mL. An eye clinic or optical wholesaler asking for Vigamox wants a 0.5% topical solution for bacterial conjunctivitis. M Care is a merchant-exporter: we supply originator or regulator-registered brands and Indian-made lines, and we confirm which one your destination's registration route accepts before quoting. The brand landscape differs by market. In the UK, emc lists Avelox tablets from Bayer plc, and the eye drops appear as Moxivig from Novartis and as a separate moxifloxacin 0.5% product from Brown & Burk UK. In the US, DailyMed lists Vigamox from Harrow Eye, LLC, while Drugs@FDA lists the Avelox tablet and injection applications as discontinued. Indian-made lines on our roster include Floxsafe and Macflox tablets and Milflox eye drops. Nothing here needs refrigeration on the labels we read, which keeps freight simple. Buyers who compare fluoroquinolones also look at levofloxacin, ciprofloxacin, ofloxacin and gemifloxacin.

Fluoroquinolone antibacterial, sourced and documented for export.

Moxifloxacin is a fluoroquinolone antibacterial (the UK SmPC class is "Quinolone antibacterials, fluoroquinolones", ATC J01MA14). The US Avelox label, FDA-hosted and revised July 2025, names Bayer HealthCare Pharmaceuticals Inc. and lists 400 mg tablets and an injection of 400 mg in 0.8% sodium chloride in a 250 mL single-dose flexible bag. It describes Avelox as a member of the fluoroquinolone class of antibacterial agents, indicated in adults 18 years of age and older, and lists community acquired pneumonia, uncomplicated and complicated skin and skin structure infections, complicated intra-abdominal infections, plague, acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis. It says to reserve Avelox, for the last two, for patients who have no alternative treatment options. Drugs@FDA lists both Avelox applications (NDA 021085 and NDA 021277) as discontinued. The UK emc SmPC for Avelox 400 mg film-coated tablets names Bayer plc as holder, first authorised 13 March 2003, and lists acute bacterial sinusitis, acute exacerbation of chronic obstructive pulmonary disease including bronchitis, community acquired pneumonia except severe cases, and mild to moderate pelvic inflammatory disease. It says the product must only be prescribed when other antibiotics commonly recommended for the infection are inappropriate, and gives one 400 mg tablet once daily. The ophthalmic family is a different label. The US Vigamox label (Harrow Eye, LLC, DailyMed label information updated January 2026) calls it a topical fluoroquinolone anti-infective for bacterial conjunctivitis caused by susceptible strains of the organisms it lists, one drop in the affected eye 3 times a day for 7 days, supplied as 3 mL in a 4 mL bottle and stored at 2 to 25 °C. The UK emc lists Moxivig 0.5% w/v eye drops (Novartis Ireland Limited as holder, first authorised 27 July 2009) for purulent bacterial conjunctivitis, in a 5 ml bottle with no special storage conditions.

What the dispensing pharmacist checks on moxifloxacin.

Adjacent lines procurement desks order alongside moxifloxacin.

Moxifloxacin supply, the specific questions.